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ABSTRACT 22 
The use of anabolic substances for growth promoting purposes in food producing animals 23 
is prohibited within the EU, yet ongoing applications of hormones such as oestradiol 24 
prove both difficult to detect and to distinguish from endogenous presence. Additionally, 25 
the misuse of glucocorticoid compounds (dexamethasone and prednisolone), which are 26 
permitted for therapeutic applications but can also promote improved animal health 27 
through long-term dosing, is reported to be increasing posing potential health concerns 28 
for consumers. Twenty-four male beef cattle were randomly assigned to four groups 29 
(n=6) for experimental treatment over 40 days consisting of a control untreated group, 30 
and three treatment groups administered oestradiol, dexamethasone or prednisolone at 31 
levels known to reflect growth promoting practices. Untargeted metabolomic profiling of 32 
plasma collected from each animal midway through the study treatment period, were 33 
analysed by reverse phase separation employing an UHPLC-QTof-MS system operating in 34 
positive electrospray ionization mode. Metabolomics analysis revealed plasma metabolite 35 
perturbations common to all treated animals, with additional metabolites found to be 36 
specifically associated with the various differing growth promoting regimes.  OPLS-DA 37 
modelling was used to discriminate plasma profiles of oestradiol, dexamethasone, or 38 
prednisolone from control untreated cohorts and found 56, 48 and 58 ions altered by the 39 
administered treatments respectively. This culminated in 99 shared ions which could 40 
distinguish between plasma samples from treated versus untreated animals. Additional 41 
assessment of the metabolites found ions which were significantly altered in comparison 42 
to control animals, of which 3, 11 and 8 ions were pertinent to oestradiol, 43 
dexamethasone or prednisolone administrations respectively. Incorporation of such 44 
markers to specific treatment types could be used at screening to facilitate further 45 
 3 
 
confirmatory analysis. Putative identification of these ions demonstrated mainly lipid 46 
components responsible for the growth promoter metabolomic effects alongside novel 47 
biomarker responses. 48 
 49 
KEYWORDS: Cattle/ Anabolic/ Blood/ Metabolite/ Screening/ Corticosteroid 50 
 51 
HIGHLIGHTS 52 
 Metabolomic profiling of bovine plasma outlines effect-based responses to growth 53 
promoter abuse and increases the capability to detect unsafe meat. 54 
 Predictive modelling based on the plasma metabolome can differentiate between 55 
samples acquired from treated and untreated animals profiles based on common 56 
metabolites of interest. 57 
 Monitoring of plasma metabolite markers specific to oestradiol, dexamethasone 58 
or prednisolone can be employed to identify the type of growth promoting regime 59 
employed 60 
 Biomarkers responses reveal the distinct modes of action of the growth promoting 61 
agents relevant to their metabolic effects. 62 
 63 
 64 
 65 
 66 
 67 
 68 
 69 
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1. INTRODUCTION  70 
The implementation of screening based testing for detection of drug residues in food 71 
producing animals is a required action within the European Union as stipulated in EC 72 
Regulation 178/2002 (2002a). Testing is assigned through National Residue Control Plans 73 
(NRCP) coordinated by European Residue Laboratories (EURLs) and results are reported 74 
to the European Food Safety Authority (EFSA) for annual review. EURLs are required to 75 
test 0.4% of slaughtered cattle numbers to meet minimum legislative requirements 76 
(Directive, 1996), and while routine regulatory monitoring finds sufficient compliance 77 
(DAFM, 2015), additional random on-farm sampling indicates continued illicit use of 78 
chemical agents within beef producing animals (Leporati et al. 2015; Imbimbo et al. 2012; 79 
Chiesa et al. 2017). The financial gains arising from illegal growth promoting 80 
administration encourages their use and exposes consumers to toxicological risk from 81 
contaminated food materials due to a combination of irregular drug use and ineffective 82 
testing (Ronquillo et al. 2017).  83 
Current test methods are dependent on direct detection analysis of known 84 
compounds with confirmatory analysis typically reliant on gas (GC) or liquid 85 
chromatography (LC) coupled to mass spectrometry (MS) methods. Despite improved 86 
sensitivity through progress in these advanced technologies, analytical challenges to the 87 
detection of growth promoter use persist (Stolker et al. 2005; van Ginkel et al. 2016). 88 
These challenges include the detection of emerging unknown compounds, identification 89 
of drug use at low doses, and effective discrimination between endogenous forms of 90 
hormones and exogenous administrations either as therapeutics or for illicit purposes 91 
(Mooney et al. 2009; Pinel et al. 2010; Courtheyn et al. 2002). The latter includes 92 
glucocorticoid and oestradiol derivatives which are increasingly abused (EFSA, 2012; Sterk 93 
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et al. 2014) due to their natural presence which is indistinguishable from external 94 
application. In this way confirmatory methods have incorporated isotope ratio (IRMS) 95 
techniques to discriminate exogenous metabolites based on the ratio of 13C/12C (Janssens 96 
et al. 2013). However, such analyses are only available through confirmatory test 97 
methods and robust screening methods are needed. As such  more research in this field is 98 
be directed towards assessment of an animal’s biological response to drug administration 99 
as a feasible alternative approach to discriminate biomarkers significant to xenobiotic 100 
exposure (Nebbia et al. 2011). In this way, Marin et al. (2008) were able to discern 101 
dexamethasone administration in finishing bulls by monitoring blood parameters, whilst 102 
Mooney et al. (2009) and Doué et al. (2015) have demonstrated biochemical screening of 103 
sex-hormone and bone markers as indicative of steroid misuse. 104 
The range of sample matrices available for anabolic screening tests varies and is 105 
dependent on the regulatory body requirements on whether the drug to be tested is 106 
acquired from live or slaughtered animals (Directive, 1996). External biological material 107 
such as urine, hair and blood can be sampled on farm, whilst consumable parts are only 108 
available after slaughter. Some metabolomic studies have been conducted with urine to 109 
distinguish treatment of oestradiol, β-agonist and prohormones (Dervilly-Pinel et al. 2011; 110 
Jacob et al. 2015;  Courant et al. 2009; Rijk et al. 2009), however there are concerns of 111 
false positive results due to faecal contamination (Arioli et al. 2010) and also endogenous 112 
prednisolone levels caused by stress (Pompa et al. 2011). Similarly, hair analysis may be 113 
subject to environmental contamination and obscured by the method of drug delivery, 114 
whilst drug residues are known to diffuse rapidly (Vanhaeke et al. 2011). For the purpose 115 
of screening, blood can be collected on farm and Noppe et al. (2008) previously reported 116 
a higher occurrence of steroid hormones within the blood due to the circulating action 117 
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from anabolic tissues and metabolomic profiling has already revealed potential 118 
biomarkers within the plasma collected (Graham et al. 2012). 119 
Metabolomic fingerprinting has been promoted as a non-targeted approach 120 
whereby the entire metabolite profile is compared to unveil markers which differ 121 
between animal cohorts (Fiehn, 2002; Dettmer et al. 2007). The acquisition of such a vast 122 
amount of data requires both bioinformatic tools to generate models which can 123 
distinguish the disrupted homeostatic state due to exogenous drug administration and 124 
predictive techniques that assign acquired data to an assumed response (Antignac et al. 125 
2011; Courant et al. 2014). Recent research incorporating the whole profile of blood 126 
metabolites to discriminate cattle exposed to growth promoting agents has been 127 
described (Regal et al. 2011; Dervilly-Pinel et al. 2012; Graham et al. 2012; Nzoughet et al. 128 
2015a), yet progress towards applicable screening approaches is as yet unrealised. 129 
Metabolites contributing to differentiating profiles have been investigated (Riedmaier et 130 
al. 2009; Pinel et al. 2010; Dervilly-Pinel et al. 2012) but their reliability is often obscured 131 
by biological and environmental conditions and the specific relevance of metabolite 132 
profiles to individual growth promoter treatments is not clear. 133 
The focus of the current study has centred on the detection of metabolomic 134 
markers significant to the misuse of glucocorticoid (dexamethasone and prednisolone) 135 
and oestradiol compounds in bovine animals for meat enhancement purposes. 136 
Glucocorticoid agents are readily available for therapeutic veterinary applications but 137 
may be misused through long-term low-dose regimes which sustain animal health whilst 138 
encouraging lean meat production (Antignac et al. 2001; Cannizzo et al. 2011). The use of 139 
oestradiol for growth promoting purposes is currently prohibited by the Scientific 140 
Committee on Veterinary Measures relating to Public Health (SCVPH) (Directive, 2003), 141 
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and whilst effective monitoring procedures have been established, it’s availability outside 142 
the EU is thought to contribute to a black market of illicit use (Courtheyn et al 2002; Regal 143 
et al. 2012) with administrations difficult to distinguish from variable endogenous levels 144 
in cattle (Regal et al. 2011).  We for the first time unveil the bovine plasma metabolome 145 
changes, detected by ultra-high performance liquid chromatography coupled to high 146 
resolution mass spectrometry (UHPLC-HRMS), significant to the administration of 147 
oestradiol, dexamethasone or prednisolone. The results illustrate the use of advanced 148 
statistical models incorporating ions altered by various treatment types to predict growth 149 
promoter exposure, whilst putative identifications highlight the possible underlying 150 
metabolite functions specific to administered compounds. 151 
152 
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2. MATERIALS AND METHODS 153 
2.1. Chemicals and reagents 154 
LC-MS grade methanol (MeOH) and formic acid (HCOOH) were purchased from Sigma 155 
Aldrich (UK).  Leucine enkephalin (Leu-Enk) was sourced from Waters (UK) and ultra-pure 156 
water (18.2 MΩ cm-1) was generated in-house using a Millipore system (Millipore, USA). 157 
 158 
2.2. Experimental design and plasma sample collection  159 
Samples were obtained from an experimental treatment study using growth promoting 160 
regimes reflective of suspected on-farm practices conveyed in the literature (Courtheyn 161 
et al. 2002; Cannizzo et al. 2008; De Maria et al. 2009). Authorized by the Italian Ministry 162 
of Health and bioethics committee of the University of Turin, the study cohort consisted 163 
of twenty four male Charolais cattle aged 17-22 months old randomly assigned to four 164 
treatment groups: Group O (n=6) received 0.01 mg/kg intramuscular injection of 17β-165 
oestradiol-3-benzoate (Sigma-Aldrich, Milan, Italy) weekly on day 12, 19, 26, 33 and 40; 166 
Group D (n=6) were administered an oral dose of 0.7 mg/day dexamethasone-21-sodium 167 
phosphate (Desashock Fort Dodge Animal Health, Bologna, Italy) for 40 days; Group P 168 
(n=6) were given 15 mg/day prednisolone acetate orally (Novosterol, Ceva Vetem SpA, 169 
Milan, Italy) for 30 days; Group C (n=6) were control untreated animals.  All animals were 170 
kept in separate housing and fed a diet of silage, corn and hay alongside a commercial 171 
protein supplement and water. Blood was collected via the jugular vein on days 0, 7, 25, 172 
35, 43 and at slaughter (day 49) using EDTA tubes for plasma preparation (centrifugation 173 
at 2,000 x g for 20 min) which was stored at −80°C.  174 
 175 
2.3. Plasma sample preparation for metabolomic profiling 176 
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Minimal sample preparation was carried out on twenty four plasma samples collected on 177 
day 25 of the animal study to ensure intact metabolite coverage with samples 178 
randomized during analysis to avoid bias in preparation. A volume of 100 μL of plasma 179 
was centrifuged at 1,000 x g for 5 mins and extraction conducted by addition of 400 μL ice 180 
cold MeOH (<20 °C), vortexing briefly and holding on ice for 20 mins. Samples were 181 
subsequently centrifuged at an increased speed of 15,000 x g for 10 mins to separate the 182 
proteinaceous pellet. The supernatant was removed and evaporated to dryness in a 183 
Savant™ SpeedVac™ concentrator (Thermo Scientific, USA) operating at 40°C, and 184 
reconstituted in 50 µL ultrapure water with 5 mins vortexing followed by filtering through 185 
a Costar® Spin-X 0.22 µm tube filter (Sigma Aldrich, UK) under centrifugation at 15,000 x 186 
g, 4°C for 2 mins. 100 µL from each of the plasma samples under investigation were 187 
pooled and similarly prepared for quality (QC) purposes. Filtered samples were stored at -188 
80°C in a LCGC Certified Clear Glass (12 x 32 mm) autosampler vial (Waters, UK) prior to 189 
UPLC-HRMS analysis.  190 
 191 
2.4. UHPLC-QTof-MS metabolomic plasma profiling   192 
Chromatographic separation was performed using an Acquity™ UPLC system (Waters, UK) 193 
comprising of a stainless steel Aquity UPLC® HSS T3 analytical column (100 x 2.1mm, 194 
particle size 1.8 μm) (Waters, UK). The column temperature was maintained at 45°C with 195 
an autosampler at 6°C. A volume of 7.5 µL sample was injected at a flow rate of 0.4 196 
mL/min and analysed over a 20 min gradient consisting of mobile phase A, HCOOH:H2O 197 
(1:1000, v/v), replaced by mobile phase B, HCOOH:MeOH (1:1000, v/v). The initial 198 
gradient was set at 1% B for 2 mins increasing to 70% B, by 7 mins to 99% B at 16.25 mins, 199 
maintained for 2.25 mins before returning to 1% B for the remaining 1.5 mins. Wash 200 
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solvent was prepared with H2O:MeOH (1:1, v/v), the seal wash was made up of 201 
H2O:MeOH (95:5, v/v) and the purge wash consisted of HCOOH:H2O (1:1000, v/v). 202 
 203 
2.5. System calibration and quality control checks 204 
A reference standard (Waters, UK) consisting of 2ng/µL nine component mix of 205 
acetaminophen, caffeine, sulfaguanidine, sulfadimethoxine, Val-Tyr-Val, verapamil, 206 
terfenadine, Leu-Enk and reserpine, was injected prior to each run (n=3) to ensure 207 
retention time and mass accuracy. The UHPLC-QTof-MS system was equilibrated with 208 
sodium formate at a flow rate of 5 µL/min with column equilibration via injection of ten 209 
replicates of pooled plasma prior to analysis and intermittent injections of pooled QC 210 
plasma throughout the run. Leu-Enk was introduced at 1 ng/µL in H2O:MeCN:HCOOH 211 
(50:50:0.1, v/v/v) to compensate for mass shift. 212 
 213 
2.6. Mass spectrometry data acquisition and processing 214 
The UHPLC system was coupled to a Xevo® G2 Q-Tof mass spectrometer and controlled 215 
via v4.1 MassLynx™ software (both from Waters, UK). Q-Tof-MS data was acquired in 216 
resolution mode. Acquisition was conducted using positive electrospray ionization mode 217 
(ESI+) with the capillary voltage set at 1 kV and the cone gas flow of 50 L/h. The source 218 
temperature was set at 120°C with 60 AU offset and the desolvation gas set at 450°C with 219 
flow rate of 850 L/h. Nitrogen was employed as the desolvation and cone gases. Data was 220 
acquired in continuum mode using MSE with scan time 0.1 sec over 50-1200 Da under 4 221 
eV low energy and a ramp of 20-35 eV at high energy. Lockmass calibration during data 222 
acquisition was set at capillary voltage 1.40 kV and collision energy 20 eV with dual point 223 
correction of Leu-Enk ([M+H]+=278.1141, 556.2771 Da) scanning for 0.2 sec at 30 s 224 
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intervals with mass window ± 0.5 Da. UHPLC-HRMS raw data files were exported for pre-225 
processing into Progenesis QI® software (Waters, UK). Chromatograms were aligned to a 226 
reference QC run and selected adducts included [M+H]+, [M+H-H2O]+, [M+Na]+, [M+K]+, 227 
[M+H-2H2O]+, and [M+CH3OH+H]+ with 2.5 AU filter. Peak picking was set to exclude ions 228 
eluted before 0.5 mins (1%) and after 14 mins (92%) at 1% and 92% organic solution, 229 
respectively. Deconvolution was applied to detect ions which may be formed from the 230 
same compound. The raw data was normalized for all compounds and exported in .CSV 231 
format for further analysis reporting selected ions by their accurate mass and retention 232 
time pair (AMRTP). Ions which demonstrated relative standard deviation (RSD) greater 233 
than 30% in QC pools were discarded from analysis. An 80% rule was also applied to 234 
eliminate any ions which were not detected in more than 80% of the samples analysed; 235 
that is, where a zero value was obtained in more than 20% of the sample set analysed, it 236 
was considered spurious and excluded from the dataset. 237 
 238 
2.7. Analysis of plasma metabolite ions discriminating between growth promoter 239 
treatment regimes 240 
2.7.1. Univariate statistics 241 
Acquired plasma metabolome datasets were first analysed using Excel 2010 (Microsoft 242 
Office, USA) for conventional statistical comparison of treated and untreated groups. 243 
Three technical replicates were averaged to provide a peak abundance of six animals per 244 
treatment group for the respective ions detected. Additionally a lower limit of 500 for the 245 
peak output was applied whereby ions showing average abundance <500 across the 246 
respective treatment groups were excluded as indistinguishable from background noise. 247 
The data was assessed for normal distribution by regression analysis and each treatment 248 
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group was tested for unequal variance via F-test against the control group. Significance of 249 
p<0.05 was then determined using a two-tailed student’s t-test comparing the control 250 
untreated group to each treated animal group, where type 2 was applied for 251 
homoscedastic variance (F>0.05) and type 3 when heteroscedastic (F<0.05).  Those ions 252 
showing significant difference in abundance when compared to the control output were 253 
considered useful for further analysis. 254 
2.7.2. Multivariate statistics 255 
SIMCA version 13.0 (Umetrics, Sweden) was used for multivariate analysis of 256 
metabolomic profiles of plasma from various treatment groups to highlight discriminatory 257 
ions. The normalized value outputs from Progenesis QI® for each sample injection, 258 
inclusive of all metabolites (<30% RSD), were subject to pareto scaling and projections 259 
were made between control and respected treated animal sets. Principal Component 260 
Analysis (PCA) enabled unsupervised separation of the test samples against the QC 261 
injections to ensure quality control samples were clustered together and check that the 262 
technical replicate injections were similarly aligned. Test samples were assigned as either 263 
control or treated for subsequent supervised analysis via orthogonal partial least squares 264 
discriminant analysis (OPLS-DA). Having obtained good prediction (Q2) and separation (R2) 265 
via OPLS-DA, S-plot and variable importance of projection (VIP) plots were utilized to 266 
select those ions contributing most to the predictive components. Markers were selected 267 
based on having a VIP score greater than 1 and subsequent jack-knifed confidence 268 
intervals with coefficient (cvSE) less than the VIP score. These were reviewed via S-plot 269 
representing positive or negative correlation p(corr) against covariance p[1] with those 270 
plotted on the outer edges of the graphical area (p[corr]>0.5) considered to have strong 271 
discriminatory power. These ions were then employed to create a new OPLS-DA model 272 
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verifying their predictive ability with 100 rounds of permutation testing alongside cross-273 
validation via CV-ANOVA. 274 
 275 
2.8. Metabolite identification 276 
Selected AMRTPs were confirmed as peaks extractable from the raw chromatogram using 277 
MassLynx™ and the theoretical elemental composition of the selected feature 278 
determined (Kind et al. 2007; Watson, 2013). Mass uncertainty was set at 5 mDa or 10 279 
ppm for those ions with MW ≤400 Da or >400 Da, respectively, and elements were 280 
restricted to C, H, O, N, P and S. The mass of the parent compound was then searched 281 
against known databases (METLIN, HMDB, PubChem) to make putative identifications in 282 
consideration of the isotope pattern and subsequent charged state with adducts 283 
confirmed against the mass spectrometry adduct calculator provided by Fiehn Lab 284 
(http://fiehnlab.ucdavis.edu/). Biological contributions were determined from 285 
subsequent PubChem classification (NCBI, USA) and corresponding KEGG (Kanehisa 286 
Laboratories, Japan) and LIPID MAPS (www.lipidmaps.org) pathway analysis. 287 
288 
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3. RESULTS AND DISCUSSION 289 
Metabolite markers specifically altered within the plasma of cattle in response to 290 
glucocorticoid and oestradiol treatment regimes were successfully reported using UHPLC-291 
HRMS metabolomics profiling.  292 
 293 
3.1 Assessment of plasma metabolome profile output  294 
A comparison of the profile of metabolites detected in bovine plasma following UHPLC-295 
HRMS analysis is displayed in Figure 1 with base peak ion chromatogram (BPI) obtained 296 
from MassLynx™ representing control, oestradiol, dexamethasone and prednisolone 297 
plasma metabolomes. Whilst it is not possible to discern obvious differences in the 298 
resulting plasma metabolome profile from the BPI, it is anticipated that any minor 299 
deviations from the untreated state could reflect xenobiotic influence and respective 300 
chromatograms were subsequently analysed via Progenesis QI® software. This enabled 301 
automated alignment, peak picking and mining of the generated metabolome dataset. 302 
The plasma metabolomic profile of each sample injection (n=72) was displayed as an ion 303 
intensity map and replicate injections were combined and matched across treatment 304 
groups for quality assurance. Resulting chromatograms conferred 3522 features detected 305 
across all runs, which were further deconvoluted to 3088 ions. Peak abundance was 306 
normalized and elimination of those ions displaying a RSD>30% in QC injection lead to a 307 
reduction of the dataset to 1364 ions. Proceeding with the application of the 80% rule, 308 
additional falsities were omitted assembling a final list of 751 metabolites suitable for 309 
multivariate analysis.  310 
 311 
3.2 Metabolite fingerprint modelling via multivariate classification 312 
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Unsupervised principal component analysis (PCA) was initially employed to compare the 313 
metabolome profiles of test samples to the QC samples from the 3088 detected features 314 
(Figure 2a). QC samples were tightly clustered demonstrating stability of the run and 315 
individual test replicate injections were similarly aligned showing repeatability of the 316 
platform performance. PCA was then used to ascertain if study groups could be classified 317 
from an unsupervised prospective based on the 751 ions of interest (Figure 2b). However, 318 
separation of control and treated profiles was not clearly distinguishable and 319 
subsequently supervised separation was applied. An OPLS-DA model was constructed 320 
from 751 variables and 63 observations based on 3 components with the control 321 
untreated profile plotted against each treated metabolome profile (Figure 3a) and 322 
demonstrated good fit based on % variation of the data set (R2X = 0.907, R2Y = 0.978) with 323 
potential to predict new data (Q2 = 0.916). Overfitting of the OPLS-DA dataset was 324 
avoided by allocating principal components based on 7 rounds of cross-validation. 325 
Furthermore, assessment of each treatment group to the control via OPLS-DA based on 326 
751 variables (Figure 3b-d), showed good separation and predictive ability of oestradiol 327 
(R2Y = 0.993, Q2 = 0.940), dexamethasone (R2Y = 0.986, Q2 = 0.943), or prednisolone (R2Y = 328 
0.890, Q2 = 0.723) plasma profiles. Interestingly, both glucocorticoid treatments 329 
demonstrated similar patterns of separation from the untreated group yet distinctive 330 
metabolome changes are further discussed. 331 
 332 
3.3 Analysis of selective ions contributing to separation 333 
The variables contributing most to the separation of untreated and treated profiles were 334 
assessed via the variable importance of projection (VIP) plot which showed 135 ions with 335 
VIP>1 within the confidence intervals4. Analysis of the VIP scores and subsequent S-plots 336 
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for each treatment type as shown in Figure 4, revealed 56 ions relevant to oestradiol 337 
treatment, 45 ions discriminating dexamethasone treatment and 58 significant to 338 
prednisolone treatment profiles. Shared and unique structure (SUS) plots were used to 339 
illustrate ions comparable across the treated profiles (Figure 5) culminating in 99 features 340 
of interest.  341 
 342 
3.4 Assessment of the predictive ability of the multivariate model 343 
The selected ions (n=99) were used to generate a new OPLS-DA model (Figure 6a) capable 344 
of discriminating treated from untreated metabolome profiles. It is anticipated that a 345 
model could indicate the use of either oestradiol, dexamethasone or prednisolone. The 346 
predictive ability of the model was tested by computing 100 rounds of iteration testing. 347 
This automatically assigned permuted points to the left with new observations lower than 348 
the original untreated on the right (see figure 6b). The regression showed sufficient 349 
separation of newly generated observations demonstrating good prediction with Q2 350 
below the X-axis (-0.62). The model was further tested by cross validation based on 2/3 of 351 
the dataset used to correctly assign the remaining 1/3. Assessment of the significance of 352 
the model by CV-ANOVA based on F-distribution of the prediction error with one degree 353 
of freedom showed significant regression (p<0.01) with p-value of 1.73 x 10-18. Similar 354 
assessment of the separate treatment group models for oestradiol, dexamethasone or 355 
prednisolone prediction showed significant classification (p<0.01) from CV-ANOVA.  356 
 357 
3.5 Statistical analysis of discriminatory ions  358 
Further assessment of the metabolic changes found 32 features at an increased level 359 
(FC>1.5) and 29 down-regulated (FC<0.5) by more than 50% in response to the various 360 
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compound administrations (Table 1a and 1b), respectively. Notably ten ions were 361 
commonly increased in all treatment groups, whilst seven ions were found to be 362 
depressed. Finally, comparison of the metabolome profile of each treatment group to the 363 
control group via student’s t-test analysis revealed 24 ions which were significantly 364 
(p<0.05) altered across the biological replicates (Table 2) and were identified as possible 365 
biomarkers of the respective growth promoter treatments. 366 
 367 
3.6 Assignment of putative identification of ions of interest 368 
The use of both high- and low-collision energies during the mass spectrometry data 369 
acquisition provided fragment rich spectra for putative identifications of the features of 370 
interest. The spectrum of each ion was extracted from a representative chromatographic 371 
peak highlighting the precursor ion. Examination of the isotope ratio confirmed the 372 
charge state as single (+), double (++) or triple (+++) in deduction of the visible adduct 373 
formation. The putative mass was matched against the fragmented spectrum and 374 
resulting identities of the 24 metabolites of interest (Table 2). The maximum mass 375 
difference observed was 12 mDa with exception of AMRTP 4.41_344.8505m/z, 376 
5.80_741.3737m/z and 6.07_618.6912m/z whose mass differences were 36.1, 16.6 and 377 
16.4, respectively. However, these adducts represent larger compounds where additional 378 
fragments available from function 2 data were incorporated to check tentative 379 
assignments. 380 
 381 
3.7 Biological classification of identified marker metabolites 382 
Putative identifications reveal the majority of functional roles relating to lipid metabolism 383 
via glycerophospholipid and sphingolipid pathways (see Fig 7) as well as fatty acid 384 
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metabolism and additional roles such as acylcarnitines, dipeptides, eicosanoids and 385 
vitamin or steroid derivatives. These findings complement biomarker candidates 386 
previously highlighted by proteomic investigation (Kinkead et al. 2015) implicating 387 
anabolic interactions with apolipoproteins and vitamin-D-binding proteins as responsible 388 
for the underlying biological mechanisms. An example of the expression levels of specific 389 
markers displayed by the differing treatment groups is shown in Figure 8 and are further 390 
discussed below. 391 
3.7.1 Phospholipids 392 
Resulting plasma metabolite identifications indicate cytidine diphosphate diacylglycerol 393 
(CDP-DG) and other glycerophospholipids including those bound to glycerol (PG, DG), 394 
inositol (PI), choline (PC) and ethanolamine (PE) as significantly preturbed by growth 395 
promoter treatment regimes. They are members of the G-protein coupled receptor family 396 
previously implicated as responsive to steroid influence (Prossnitz et al. 2008) ) and 397 
significantly altered by growth promoter treatment (Nzoughet et al. 2015b).. These 398 
glycerophospholipids are known to play an important role in the generation of 399 
triacylglycerides from glycerol-3-phosphate by acting on phosphatidic acid and 400 
contributing metabolic functions (Stapleton et al. 2011). However plasma levels of PG 401 
(18:4(6Z,9Z, 12Z,15Z)/12:0) were also shown to be reduced by growth promoter 402 
treatment in this study as it is known to be cleaved to form diacylglycerol. The fluctuating 403 
levels are probably due to the relative transformation state but may also be dependent 404 
on the agent administered. Others (Kitson et al. 2013) found increased plasma 405 
phospholipid levels in rats supplemented with 17β-oestradiol whilst Nzoughet et al. 406 
(2015b) reported a decrease in PG, PI, PA, PE, PC upon administration of trenbolone 407 
acetate.  It is known that these phospholipids are important in the generation of 408 
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triacylglycerides and subsequent metabolic functions (Stapleton et al. 2011). Additionally 409 
LysoPC was notably increased in the study and is formed in plasma by a specific enzyme 410 
system, lecithin-cholesterol acyltransferase (LCAT) which catalyzes the transfer of fatty 411 
acids to free cholesterol bound to high/low density lipoproteins (H/LDL). This 412 
complements previous proteomic analysis showing increased levels of apolipoproteins A1 413 
and AIV (Kinkead et al. 2015). 414 
 415 
3.7.2 Sphingolipids 416 
Treatment of cattle with oestradiol, dexamethasone or prednisolone resulted in a 417 
dramatic increase in the level of plasma sphingolipids in this study. Sphingolipids have 418 
been shown to modulate the steroid hormone biosynthetic pathway at multiple levels, 419 
including gene expression, steroidogenic activity and act as second messengers in 420 
signalling cascades (Lucki, Sewer 2008; Sabourdy et al. 2008). Studies have shown 421 
demonstrable increased levels associated with insulin resistance and contributing 422 
metabolic disorders where glucocorticoids are known to have large and specific effects on 423 
sphingolipid expression (Holland, Summers, 2008). Specifically, ganglioside GT1b, 6Galβ1, 424 
Galα1-3, GM3 were increased most by prednisolone administration in this study with 425 
observable fold change differences ranging from 3-11 times the peak output from the 426 
untreated plasma metabolite profile. These gangliosides make up the cell membrane and 427 
are involved in signal transduction mediated by the liver contributing to lipoprotein 428 
sialylation and cholesterol efflux through inhibition of glycerophospholipids (Millar, 2001, 429 
Subbaiah et al. 1993). Previous reports indicate dysregulation of sphingolipids having 430 
profound effects on glycerophospholipid expression in plasma (Rodrigues-Cuenca et al. 431 
2017). Sphingolipids can be found in all tissues and biofluids since they contribute largely 432 
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to the immune responseg (Garcia-Barros et al. 2015). Furthermore, gangliosides are 433 
known to inhibit pro-inflammatory signals (Miklavcic et al. 2012) which may explain why 434 
they are increased herein more so by prednisolone due to its anti-inflammatory action.)  435 
 436 
3.7.3 Fatty acid synthesis 437 
An increase in 6-oxocyclohex-1-ene-1-carboxyl-CoA was displayed across all treatments in 438 
this study and has not previously been reported relevant to the bovine growth promoter 439 
response. We know acyl-Coenzyme A plays a key role in fatty acid metabolism as well as 440 
lipid synthesis and expression levels are altered by anabolic influence for energy 441 
production (Zhao et al. 2016; Pietrocola et al. 2015). Whilst oestradiol administration 442 
resulted in the greatest increase in CoA in this study, the levels expressed were shown to 443 
be most significantly evident in dexamethasone treated animals with lower levels 444 
displayed by the prednisolone treatment group. Other studies have found increased 445 
expression of the CoA gene after administration with prohormone 446 
dehydroepiandrosterone for the purpose of growth promotion in cattle (Rijk et al. 2010). 447 
Acyl CoA is also influenced by glucose homeostasis with increased expression resulting in 448 
high uptake of fatty acids in adipose tissue and increased triacylglycerol synthesis (Zhao et 449 
al. 2016). Fatty acid metabolites N-stearoyl tyrosine and hypusine were notably decreased 450 
after growth promoter treatment hereinand may reflect the feedback redirection of acyl 451 
thioesters from plasma via CoA binding proteins (Faergeman, Knudsen 1997). 452 
 453 
 454 
3.7.4 Acylcarnitines 455 
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The level of acylcarnitines in the plasma metabolome of growth promoter treated animals 456 
was found to be reduced in comparison to that of untreated animals. Specifically, 457 
hepatonylcarnitine was reduced by up to 73% and found to be significantly depressed by 458 
oestradiol treatment, whilst other stearidonyl carnitine and 12-hydroxy-12-459 
octadecanoylcarnitine were found to be significantly reduced within the dexamethasone 460 
metabolome profile. Acylcarnitines are predominantely derived from β-oxidation of fatty 461 
acids and increased levels are known to contribute to fatty acid metabolism to meet 462 
energy demands whilst decreased utilization of fatty acids would lead to decreased 463 
acylcarnitine expression (Hoppel, 2003; Thompson et al. 2012).The regulation of 464 
acylcarnitines is interestingly mediated by CoA with accumulated response to 465 
inflammation, insulin sensitivity and other signal transduction events (McCoin et al. 2015).  466 
 467 
3.7.5 Eicosanoids 468 
An increase in the level of an eicosanoid was observed across all growth promoter treated 469 
plasma profiles. Eicosanoids are synthesised from arachidonic acid and are involved in 470 
autocrine and paracrine response (Nebert, Russel, 2002) operated via G protein receptors 471 
through lipid signalling pathways (Funk, 2001). They have not previously been implicated 472 
in the bovine growth promoter response but are known to be anti-inflammatory 473 
mediators (Salmon, Higgs 1987) and specifically leukotriene E3 was significant to 474 
prednisolone administration.  475 
 476 
3.7.6 Additional metabolites 477 
Interestingly, the dipeptide tryptophyl-proline was shown to be increased in the plasma 478 
of cattle exposed to growth promoter treatments in this study alongside isoleucyl-479 
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tryptophan which was significant to the dexamethasone treatment group. Regal et al. 480 
(2014) also reported an increase in pyroglutamyl-phenylalaninedipeptide as a biomarker 481 
of oestradiol administration. Such increases may be attributed to roles in protein 482 
metabolism but their specific action in the growth promoter response remains unclear.  483 
Other metabolites of interest were found to be significantly reduced in response to 484 
dexamethasone treatment including a bile acid (Chenodeoxycholic acid glycine 485 
conjugate), vitamin D3 derivative (3'-O-Aminopropyl-25-hydroxyvitamin D3) and steroid 486 
metabolite (1'H-5alpha-Cholest-2-eno[3,2-b]indole), which is indicative of additional 487 
biological pathways affected by corticosteroid metabolism. Moreover, an increase in 3-488 
methylene-indolenine within oestradiol and prednisolone treatment metabolome profiles 489 
is not clear since it functions as a catalyst in the formation of reactive intermediates from 490 
pneumotoxic chemicals via cytochrome P450. An additional marker ion 491 
(6.80_989.5636m/z) shown to be significantly increased in response to oestradiol 492 
treatment could not be identified from available metabolite databases.  493 
 494 
4. Conclusions 495 
Given the many issues which compromise the effective and sensitive monitoring of illegal 496 
growth promoter use in food production, it is clear that new strategies are required to 497 
more confidently determine cases of anabolic exposure that do not solely focus on 498 
concentration levels of drugs or their metabolites which can be eliminated rapidly or are 499 
autogenously present. The work herein demonstrates the capability of metabolomic 500 
screening methods to identify bovine animals subjected to various types of growth 501 
promoting treatment regimes. This is the first investigation of alterations to the 502 
metabolome detectable within plasma relevant to prednisolone, dexamethasone or 503 
 23 
 
oestradiol administrations, with 58, 45 and 56 ions observed to be significantly altered in 504 
response to growth promoter treatments. Predictive modelling was shown to 505 
successfully discriminate between the metabolome profiles of plasma from treated and 506 
untreated animals based on 99 perturbed metabolite ions. Putative identification of 507 
specific metabolites enables the development of candidate markers significant to 508 
oestradiol, dexamethasone or prednisolone administration. These were mostly 509 
attributed to sphingolipid and glycerophospholipid pathways relevant to fatty acid 510 
synthesis with implications on cholesterol transport, glycolysis and immune responses. 511 
The differing responses relative to the level of drug exposure is yet to be determined but 512 
it is anticipated that further development of these gangliosides, lipoproteins, Co-enzyme 513 
A, acylcarnitines and eicosanoids into rapid onsite screening tools could detect cases of 514 
drug misuse prior to confirmatory analysis.  515 
 516 
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FIGURE CAPTIONS 729 
Figure 1. REPRESENTATIVE BASE PEAK ION CHROMATOGRAM OF BOVINE PLASMA 730 
METABOLOME - from A) control, B) oestradiol, C) dexamethasone, D) prednisolone 731 
obtained from UHPLC-HRMS profiling in positive electrospray ionization mode across an 732 
increasing methanol gradient. 733 
 734 
Figure 2. MULTIVARIATE DATA ANALYSIS OF METABOLITE PROFILES OF PLASMA FROM 735 
PCA SCORES PLOT - of A) unsupervised separation of QC vs test data based on 3088 736 
detected features; B) unsupervised separation of control from treated plasma metabolite 737 
profiles based on 751 ions of interest. 738 
 739 
Figure 3. OPLS-DA CLASSIFICATION OF FEATURES (n=751) ACQUIRED FROM PLASMA 740 
METABOLOME PROFILES - of A) untreated vs treated, B) untreated vs oestradiol, C) 741 
untreated vs dexamethasone, D) untreated vs prednisolone. Data was previously 742 
subjected to pareto scaling and separation shown is based on the first two components. 743 
 744 
Figure 4. VIP PLOT OF CONTRIBUTING VARIABLES - highlighted from the OPLS-DA model. 745 
135 ions demonstrating VIP>1 and cvSE<VIP were selected for further analysis as 746 
potential marker metabolites. 747 
 748 
Figure 5. CONSTRUCTED S-PLOT OF FEATURES (n=751) DETECTED FROM BOVINE PLASMA 749 
GENERATED BY OPLS-DA MODEL - comparing control untreated to A) oestradiol B) 750 
dexamethasone C) prednisolone profiles. Ions highlighted red possess VIP>1 and 751 
demonstrate strong discriminatory power with p[1] >0.05 and p(corr[1])>0.1. The 752 
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positively correlated features are upregulated whilst negative features correspond to 753 
down regulation in the treated state. 754 
 755 
Figure 6. SUS PLOT OF THE TREATED PROFILES - separating control from oestradiol (M70), 756 
dexamethasone (M69), prednisolone (M71) highlighting ions of interest as previously 757 
selected from OPLS-DA models. Comparison of markers between A) oestradiol to 758 
dexamethasone, B) dexamethasone to prednisolone, and C) oestradiol to prednisolone. 759 
The variables lying across the diagonal are shared across the treatment types whereas the 760 
outer boxes reveal those markers specific to the treatment profile where red-outlined box 761 
denotes those specific to the y-axis model and the blue-outlined box denotes those 762 
relevant to the x axis model. The number of commonly altered ions are depicted in D) a 763 
venn diagram based on 99 ions of interest. 764 
 765 
Figure 7. CLASSIFICATION OF SIGNIFICANT MARKERS - Elucidation of the biological 766 
contribution of the 24 metabolites identified show over a third are relevant to lipids of 767 
which function as either phospholipids or sphingolipids. Another third function as fatty 768 
acyl or acyl carnitines, with the remaining metabolites involved in cell signalling and 769 
metabolism, and only one metabolite remained unidentifiable.770 
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TABLES 771 
Table 1a RESULTING IONS OF INTEREST – found at increased levels in treated animals 772 
compared to non-treated. Represented by AMRTP showing the average peak output 773 
within the control untreated group and relative fold change >1.5 in red alongside the VIP 774 
score and p-value determined from student’s t-test (n=6) highlighted in green as 775 
significant (<0.05). Ten ions are shown commonly upregulated across all treatment types. 776 
 777 
Table 1b RESULTING IONS OF INTEREST – found at decreased levels in treated animals 778 
compared to non-treated. Represented by AMRTP showing the average peak output 779 
within the control untreated group and relative fold change <0.5 in yellow alongside the 780 
VIP score and p-value determined from student’s t-test (n=6) highlighted in green as 781 
significant (<0.05). Seven ions commonly decreased by all treatment types. 782 
 783 
Table 2 PUTATIVE IDENTIFICATION OF METABOLITES – 24 plasma metabolites shown to 784 
be cumulatively increased or decreased across the treatment profiles in comparison to 785 
control untreated (p<0.05), were assigned identifications by accurate mass based on the 786 
isotope charge (+, ++, +++) matching the formed adduct. Elemental composition analysis 787 
predicted chemical formulae and corresponding assignments show a mass difference <11 788 
mDa with exception of * ions which were confirmed by additional fragments present. 789 
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FIGURE 1 790 
791 
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FIGURE 2792 
A) 
B) 
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FIGURE 3793 
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FIGURE 4794 
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R2X = 0.818 
R2Y = 0.993 
Q2 = 0.940 
R2X = 0.771 
R2Y = 0.986 
Q2 = 0.943 
A) B) 
R2X = 0.567 
R2Y = 0.89 
Q2 = 0.723 
C) 
FIGURE 5795 
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FIGURE 6796 
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FIGURE 7797 
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TABLE 1a 798 
799 
AMRTP 
UNTREATED 
Peak 
Output 
Oestradiol Dexamethasone Prednisolone 
VIP 
FC p  FC p FC p 
3.77_312.1489m/z 660 4.07 0.066 3.88 0.038 1.81 0.250 1.2 
4.41_344.8505m/z 872 4.23 0.038 3.04 0.240 3.77 0.032 1.4 
5.56_437.7554m/z 1225 3.11 0.064 2.30 0.211 1.62 0.066 1.3 
5.80_741.3737m/z 246 10.75 0.065 6.76 0.293 8.72 0.028 1.3 
6.08_463.0078n 3415 6.87 0.092 1.97 0.419 5.04 0.022 1.2 
6.07_618.6912m/z 16072 3.40 0.074 1.52 0.484 3.34 0.013 2.4 
6.17_662.8879m/z 8069 2.43 0.117 1.55 0.357 2.56 0.017 2.0 
6.18_442.2595m/z 2180 2.32 0.137 1.60 0.345 2.89 0.031 1.5 
6.31_391.2184n 9545 1.91 0.097 1.72 0.251 1.51 0.207 1.6 
6.51_593.3530n 10254 2.90 0.067 1.95 0.192 1.97 0.024 2.3 
5.04_338.0986m/z 4161 1.53 0.063 1.53 0.147 1.30 0.181 1.1 
6.27_806.8828m/z 8805 1.93 0.370 3.62 0.207 1.33 0.664 2.1 
6.80_989.5636m/z 7695 2.04 0.028 1.51 0.372 1.26 0.648 1.6 
4.38_246.6527n 9928 1.98 0.037 1.34 0.443 1.83 0.067 1.7 
6.01_560.3267m/z 2057 1.96 0.123 1.15 0.774 2.02 0.032 1.1 
6.59_130.0697m/z 780 1.60 0.316 1.08 0.816 2.78 0.045 1.0 
3.40_381.7018n 3260 1.62 0.159 1.43 0.389 1.19 0.594 1.2 
3.50_349.1792n 9427 1.55 0.377 0.68 0.376 1.39 0.471 1.2 
3.98_506.6963n 3283 1.78 0.119 1.33 0.539 1.21 0.632 1.3 
3.42_314.1654n 10285 0.58 0.199 1.72 0.256 0.71 0.381 1.7 
4.19_532.9512m/z 8787 1.08 0.917 1.83 0.619 0.50 0.365 1.3 
4.29_572.3757m/z 15060 0.89 0.839 1.95 0.182 0.81 0.623 1.9 
4.30_473.3004m/z 1928 0.87 0.864 2.21 0.218 0.54 0.362 1.0 
5.26_340.1144m/z 1693 1.36 0.240 2.06 0.044 1.49 0.104 1.1 
5.45_694.0660m/z 5424 0.80 0.808 2.65 0.224 0.54 0.376 1.8 
6.29_1049.5044n 6745 1.10 0.805 1.64 0.411 1.47 0.442 1.5 
6.38_846.8671m/z 10334 0.88 0.847 2.12 0.371 0.67 0.622 1.7 
4.07_423.5427m/z 42359 1.37 0.259 0.75 0.367 1.67 0.130 4.4 
4.08_477.5618m/z 2226 0.82 0.636 0.62 0.376 1.83 0.143 2.3 
4.68_285.6390n 5848 1.34 0.363 1.12 0.708 1.52 0.165 1.2 
4.82_556.7827n 24546 1.19 0.684 0.98 0.960 1.51 0.236 3.2 
13.97_552.4253m/z 13655 1.08 0.747 0.73 0.373 1.62 0.196 2.3 
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 800 
TABLE 1b 801 
AMRTP 
UNTREATED 
Peak 
Output 
Oestradiol Dexamethasone Prednisolone 
VIP 
FC p FC p FC p 
4.00_393.7204n 11219 0.20 0.122 0.38 0.207 0.25 0.141 1.6 
4.46_229.1634m/z 31223 0.32 0.176 0.37 0.208 0.18 0.119 3.5 
4.96_415.2549n 8338 0.13 0.193 0.36 0.314 0.09 0.176 1.6 
5.83_579.0046n 4361 0.08 0.305 0.43 0.502 0.06 0.295 1.2 
6.00_394.2106m/z 2559 0.11 0.061 0.46 0.227 0.16 0.071 1.2 
6.32_440.8133m/z 3093 0.14 0.251 0.25 0.308 0.13 0.246 1.1 
6.38_594.8657m/z 8444 0.50 0.476 0.22 0.243 0.29 0.280 1.7 
8.23_552.3425m/z 7757 0.40 0.114 0.23 0.022 1.22 0.779 1.7 
3.08_203.1468m/z 3579 0.37 0.207 0.57 0.462 0.28 0.161 1.2 
3.28_337.1815n 70619 0.27 0.125 0.53 0.244 0.27 0.127 3.8 
5.98_618.7759m/z 20357 0.24 0.110 0.64 0.390 0.30 0.132 1.9 
9.94_561.3523n 1830 0.21 0.114 0.72 0.483 0.39 0.168 1.1 
11.42_228.2382m/z 2856 0.27 0.028 0.57 0.290 0.44 0.076 1.2 
0.72_229.1280m/z 1342 1.07 0.909 0.22 0.069 0.24 0.073 1.1 
4.24_ 344.2161m/z 4795 0.67 0.224 0.35 0.022 0.40 0.032 1.5 
4.89_388.7325m/z 1794 0.58 0.537 0.28 0.218 0.34 0.293 1.0 
10.69_296.2437n 21128 0.47 0.102 0.65 0.288 0.78 0.567 1.9 
5.45_318.1921m/z 10303 0.52 0.086 0.33 0.021 0.55 0.128 1.7 
11.34_452.3281m/z 27232 0.79 0.411 0.42 0.036 1.03 0.937 1.9 
11.49_494.3394m/z 14328 1.17 0.576 0.46 0.061 0.99 0.964 1.8 
11.64_481.3341n 37684 0.95 0.833 0.40 0.022 0.99 0.984 2.5 
11.99_495.3517n 74675 0.88 0.495 0.45 0.010 0.89 0.547 3.5 
12.06_465.3376n 60724 0.74 0.256 0.41 0.019 1.08 0.820 3.4 
12.82_480.3605m/z 37793 0.55 0.078 0.32 0.012 0.79 0.532 2.7 
12.97_959.7157m/z 9751 0.51 0.164 0.15 0.062 0.85 0.794 1.5 
13.13_482.3789m/z 26818 0.72 0.331 0.40 0.050 0.77 0.478 2.1 
13.30_506.3807m/z 22355 0.82 0.500 0.43 0.052 0.91 0.813 1.6 
13.42_494.3792m/z 24518 0.61 0.194 0.33 0.049 0.80 0.555 2.2 
13.47_508.3950m/z 16785 0.87 0.647 0.45 0.092 0.71 0.333 1.9 
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TABLE 2 803 
804 
Treatment FC p m/z 
RT 
(min) 
Isotope 
Charge 
Elemental 
Composition 
Mass Adduct MW 
Mass 
Diff 
(mDa) 
Compound CID 
(PubChem) 
Class 
Oestradiol 
Prednisolone 
+ 
0.038 
0.032 
344.8505 4.41 
344.8449+++ 
>516.7748++ 
>1032.5249+ 
C48H89N3O15P2 1032.5661 M+Na 1009.58 -36.10* CDP-DG(18:0/18:0) 53477922 Glycerophospholipid 
Dexamethasone 
Prednisolone 
- 
0.022 
0.032 
344.2161 4.24 
344.1996++ 
>687.3996+ 
C36H63O10P 344.2152 M+2H 686.42 0.94 
PG(18:4(6Z,9Z, 
12Z,15Z)/12:0) 
52926690 Glycerophospholipid 
Oestradiol + 0.028 989.5636 6.80 989.5685+ C45H90N3O14P3 
  
    Unknown   
Oestradiol + 0.037 247.6600 4.38 
247.6608++ 
>494.3061+ 
C24H48NO7P 247.6657 M+2H 493.32 -5.71 LysoPC(16:1(9Z)) 24779461 Glycerophospholipid 
Oestradiol - 0.028 228.2382 11.42 228.2345+ C14H27NO4 228.2228 M+2Na+H 273.19 11.50 Heptanoylcarnitine 6426896 Acylcarnitine 
Dexamethasone + 0.038 312.1489 3.77 312.1359+++ C28H42N7O18P3S 312.1502 M+H+2Na 889.15 -1.29 
6-Oxocyclohex-1-ene-
1-carboxyl-CoA 
442450 Fatty Acyl Thioesters 
Dexamethasone + 0.044 340.1144 5.26 340.1026+ C16H19N3O3 340.1058 M+H 301.34 8.55 Tryptophyl-Proline 23980# Dipeptide 
Dexamethasone + 0.022 552.3425 8.23 552.3353+ C26H54NO6P 552.3400 M+2Na-H 507.37 2.50 PC(O-18:1(11Z)/0:0) 21672239 Glycerophospholipid 
Dexamethasone + 0.021 318.1921 5.45 318.1846+ C17H23N3O3 318.1812 M+H 317.17 10.93 Isoleucyl-Tryptophan 85823# Dipeptide 
Dexamethasone - 0.036 452.3281 11.34 452.3184+ C25H41NO4 452.3370 M+CH3OH+H 419.30 -8.94 Stearidonyl carnitine 53477835 Acylcarnitine 
Dexamethasone - 0.022 482.3414 11.64 482.3299+ C23H48NO7P 482.3476 M+CH3OH+H 449.31 -6.19 
Chenodeoxycholic acid 
glycine conjugate 
12544 Bile acid 
Dexamethasone - 0.010 496.3590 11.99 496.3498+ C30H51NO2 496.3551 M+K 457.39 3.90 
3'-O-Aminopropyl-25-
hydroxyvitamin D3 
12020395 Secosteroid 
Dexamethasone - 0.019 466.3449 12.06 466.3354+ C25H49NO5 466.3503 M+Na 443.36 -5.37 
12-Hydroxy-12-
octadecanoylcarnitine 
53481632 Acylcarnitine 
Dexamethasone - 0.012 480.3605 12.82 480.3422+ C27H45NO4 480.3683 M+CH3OH+H 447.33 -7.80 N-stearoyl tyrosine 6710116 Fatty Acyl Amide 
Dexamethasone - 0.050 482.3789 13.13 482.3703+ C33H49N 482.3757 M+Na 459.39 3.18 
1'H-5alpha-Cholest-2-
eno[3,2-b]indole 
17396442 Steroid Metabolite 
Dexamethasone - 0.049 494.3792 13.42 494.3606+ C10H23N3O3 494.3710 2M+3H2O+2H 455.40 8.15 Hypusine 65396 Hydroxy Fatty Acyl 
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 805 
TABLE 2 cont’d 806 
 807 
Treatment FC p m/z 
RT 
(min) 
Isotope 
Charge 
Elemental  
Composition 
Mass Adduct MW 
Mass Diff 
(mDa) 
Compound 
CID 
(PubChem) 
Class 
Prednisolone + 0.028 741.3737 5.80 
741.3531+
++ 
C98H170N4O47 741.3571 M+3Na 2155.10 16.60* 
Ganglioside GT1b 
(d18:1/20:0) 
53481259 Sphingolipid 
Prednisolone + 0.022 927.5272 6.08 
927.5300+
+ 
C87H154N4O36 927.5154 M+H+Na 1831.03 11.83 
NeuAcα2-6Galβ1-
4GlcNAcβ1-
3(GlcNAcβ1-
6)Galβ1-4Glcβ-
Cer(d18:1/24:1(15Z
)) 
44262970 Sphingolipid 
Prednisolone + 0.013 618.6912 6.07 
618.6761+
++ 
C86H156N2O37 618.6748 M+2Na+H 1809.04 16.44* 
Galα1-3(Fucα1-
2)Galβ1-
3GalNAcβ1-3Galα1-
3Galβ1-4Glcβ-
Cer(d18:1/24:0) 
44260248 Sphingolipid 
Prednisolone + 0.017 663.3882 6.17 
662.8710+
+ 
C33H63O13P 663.3879 M+H-2H2O 698.40 0.29 PI(12:0/12:0) 52928414 
Glycerophospholip
id 
Prednisolone + 0.031 442.2595 6.18 442.2406+ C23H39NO5S 442.2622 M+H 441.25 -2.69 Leukotriene E3 6440643 Eicosanoid 
Prednisolone + 0.024 594.3603 6.51 
594.3479+
+ 
C58H104N2O21 594.3548 M+H+Na 1164.71 5.45 
Ganglioside GM3 
(d18:1/9Z-18:1) 
20057284 Sphingolipid 
Prednisolone + 0.032 560.3267 6.01 560.3235+ C26H52NO7P 560.3322 M+Na 537.34 -5.51 PE(9:0/12:0)[U] 40678# 
Glycerophospholip
id 
Prednisolone + 0.045 130.0697 6.59 130.0663+ C9H7N 130.0651 M+H 129.06 4.56 
3-Methylene-
indolenine 
170404 Indole 
